Impact of angiotensin converting enzyme inhibitors/angiotensin receptors blockers on mortality in acute heart failure patients with left ventricular systolic dysfunction in the middle east

Observations from the Gulf Acute Heart Failure Registry (Gulf CARE)

Ibrahim Al-Zakwani, Kadhim Sulaiman, Jawad A. Al-Lawati, Alawi A. Alsheikh-Ali, Prashanth Panduranga, Khalid F. Al-Habib, Jassim Al Suwaidi, Wael Al-Mahmeed, Hussam Al-Faleh, Abdelfatah Elasfar, Ahmed Al-Motarreb, Mustafa Ridha, Bassam Bulbanat, Mohammed Al-Jarallah, Nooshin Bazargani, Nidal Asaad, Haitham Amin

Research output: Contribution to journalArticle

Abstract

Aims: To evaluate the impact of Angiotensin-Converting Enzyme Inhibitors (ACEIs)/ Angiotensin Receptors Blockers (ARBs) on in-hospital, 3-and 12-month all-cause mortality in Acute Heart Failure (AHF) patients with left ventricular systolic dysfunction in 7 countries of the Middle East. Methods and Results: Data was analysed from 2,683 consecutive patients admitted with AHF and Left Ventricular Ejection Fraction (LVEF) (<40%) from 47 hospitals from February to November 2012. Analyses were evaluated using univariate and multivariate statistics. The overall mean age of the cohort was 58±15, 72% (n=1,937) were males, 62% (n=1,651) had coronary artery disease, 57% (n=1,539) were hypertensives and 47% (n=1,268) had diabetes. Overall cumulative mortality at inhospital, 3-and 12-month follow-up was 5.8% (n=155), 12.6% (n=338) and 20.4% (n=548), respectively. Adjusting for demographic and clinical characteristics as well as medication in a multivariate logistic regression model, ACEIs were associated with lower risk of in-hospital mortality (adjusted odds ratio (aOR), 0.48; 95% Confidence Interval (CI): 0.25 to 0.94; p=0.031). At 3-month follow-up, both ACEIs (aOR, 0.64; 95% CI: 0.43 to 0.95; p=0.025) and ARBs (aOR, 0.34; 95% CI: 0.18 to 0.62; p<0.001) were associated with lower risk of mortality. Additionally, at 12-month follow-up, those prescribed ACEIs (aOR, 0.71; 95% CI: 0.53 to 0.96; p=0.027) and ARBs (aOR, 0.47; 95% CI: 0.31 to 0.71; p<0.001) were still associated with lower risk of mortality. Conclusion: ACEIs and ARBs treatments were associated with lower mortality risk during admission and up to 12-month of follow-up in Middle East AHF patients with left ventricular systolic dysfunction.

Original languageEnglish
Pages (from-to)596-602
Number of pages7
JournalCurrent Vascular Pharmacology
Volume16
Issue number6
DOIs
Publication statusPublished - Jan 1 2018

Fingerprint

Middle East
Angiotensin Receptor Antagonists
Left Ventricular Dysfunction
Angiotensin-Converting Enzyme Inhibitors
Registries
Heart Failure
Odds Ratio
Confidence Intervals
Mortality
Hospital Mortality
Logistic Models
Stroke Volume
Coronary Artery Disease
Demography

Keywords

  • Angiotensin receptor antagonists
  • Angiotensin-converting enzyme inhibitors
  • Ejection fraction
  • Heart failure
  • Middle East
  • Mortality

ASJC Scopus subject areas

  • Pharmacology
  • Cardiology and Cardiovascular Medicine

Cite this

Impact of angiotensin converting enzyme inhibitors/angiotensin receptors blockers on mortality in acute heart failure patients with left ventricular systolic dysfunction in the middle east : Observations from the Gulf Acute Heart Failure Registry (Gulf CARE). / Al-Zakwani, Ibrahim; Sulaiman, Kadhim; Al-Lawati, Jawad A.; Alsheikh-Ali, Alawi A.; Panduranga, Prashanth; Al-Habib, Khalid F.; Al Suwaidi, Jassim; Al-Mahmeed, Wael; Al-Faleh, Hussam; Elasfar, Abdelfatah; Al-Motarreb, Ahmed; Ridha, Mustafa; Bulbanat, Bassam; Al-Jarallah, Mohammed; Bazargani, Nooshin; Asaad, Nidal; Amin, Haitham.

In: Current Vascular Pharmacology, Vol. 16, No. 6, 01.01.2018, p. 596-602.

Research output: Contribution to journalArticle

Al-Zakwani, I, Sulaiman, K, Al-Lawati, JA, Alsheikh-Ali, AA, Panduranga, P, Al-Habib, KF, Al Suwaidi, J, Al-Mahmeed, W, Al-Faleh, H, Elasfar, A, Al-Motarreb, A, Ridha, M, Bulbanat, B, Al-Jarallah, M, Bazargani, N, Asaad, N & Amin, H 2018, 'Impact of angiotensin converting enzyme inhibitors/angiotensin receptors blockers on mortality in acute heart failure patients with left ventricular systolic dysfunction in the middle east: Observations from the Gulf Acute Heart Failure Registry (Gulf CARE)', Current Vascular Pharmacology, vol. 16, no. 6, pp. 596-602. https://doi.org/10.2174/1570161115666170817164420
Al-Zakwani, Ibrahim ; Sulaiman, Kadhim ; Al-Lawati, Jawad A. ; Alsheikh-Ali, Alawi A. ; Panduranga, Prashanth ; Al-Habib, Khalid F. ; Al Suwaidi, Jassim ; Al-Mahmeed, Wael ; Al-Faleh, Hussam ; Elasfar, Abdelfatah ; Al-Motarreb, Ahmed ; Ridha, Mustafa ; Bulbanat, Bassam ; Al-Jarallah, Mohammed ; Bazargani, Nooshin ; Asaad, Nidal ; Amin, Haitham. / Impact of angiotensin converting enzyme inhibitors/angiotensin receptors blockers on mortality in acute heart failure patients with left ventricular systolic dysfunction in the middle east : Observations from the Gulf Acute Heart Failure Registry (Gulf CARE). In: Current Vascular Pharmacology. 2018 ; Vol. 16, No. 6. pp. 596-602.
@article{43ce412713534962b7af3f040c0189a9,
title = "Impact of angiotensin converting enzyme inhibitors/angiotensin receptors blockers on mortality in acute heart failure patients with left ventricular systolic dysfunction in the middle east: Observations from the Gulf Acute Heart Failure Registry (Gulf CARE)",
abstract = "Aims: To evaluate the impact of Angiotensin-Converting Enzyme Inhibitors (ACEIs)/ Angiotensin Receptors Blockers (ARBs) on in-hospital, 3-and 12-month all-cause mortality in Acute Heart Failure (AHF) patients with left ventricular systolic dysfunction in 7 countries of the Middle East. Methods and Results: Data was analysed from 2,683 consecutive patients admitted with AHF and Left Ventricular Ejection Fraction (LVEF) (<40{\%}) from 47 hospitals from February to November 2012. Analyses were evaluated using univariate and multivariate statistics. The overall mean age of the cohort was 58±15, 72{\%} (n=1,937) were males, 62{\%} (n=1,651) had coronary artery disease, 57{\%} (n=1,539) were hypertensives and 47{\%} (n=1,268) had diabetes. Overall cumulative mortality at inhospital, 3-and 12-month follow-up was 5.8{\%} (n=155), 12.6{\%} (n=338) and 20.4{\%} (n=548), respectively. Adjusting for demographic and clinical characteristics as well as medication in a multivariate logistic regression model, ACEIs were associated with lower risk of in-hospital mortality (adjusted odds ratio (aOR), 0.48; 95{\%} Confidence Interval (CI): 0.25 to 0.94; p=0.031). At 3-month follow-up, both ACEIs (aOR, 0.64; 95{\%} CI: 0.43 to 0.95; p=0.025) and ARBs (aOR, 0.34; 95{\%} CI: 0.18 to 0.62; p<0.001) were associated with lower risk of mortality. Additionally, at 12-month follow-up, those prescribed ACEIs (aOR, 0.71; 95{\%} CI: 0.53 to 0.96; p=0.027) and ARBs (aOR, 0.47; 95{\%} CI: 0.31 to 0.71; p<0.001) were still associated with lower risk of mortality. Conclusion: ACEIs and ARBs treatments were associated with lower mortality risk during admission and up to 12-month of follow-up in Middle East AHF patients with left ventricular systolic dysfunction.",
keywords = "Angiotensin receptor antagonists, Angiotensin-converting enzyme inhibitors, Ejection fraction, Heart failure, Middle East, Mortality",
author = "Ibrahim Al-Zakwani and Kadhim Sulaiman and Al-Lawati, {Jawad A.} and Alsheikh-Ali, {Alawi A.} and Prashanth Panduranga and Al-Habib, {Khalid F.} and {Al Suwaidi}, Jassim and Wael Al-Mahmeed and Hussam Al-Faleh and Abdelfatah Elasfar and Ahmed Al-Motarreb and Mustafa Ridha and Bassam Bulbanat and Mohammed Al-Jarallah and Nooshin Bazargani and Nidal Asaad and Haitham Amin",
year = "2018",
month = "1",
day = "1",
doi = "10.2174/1570161115666170817164420",
language = "English",
volume = "16",
pages = "596--602",
journal = "Current Vascular Pharmacology",
issn = "1570-1611",
publisher = "Bentham Science Publishers B.V.",
number = "6",

}

TY - JOUR

T1 - Impact of angiotensin converting enzyme inhibitors/angiotensin receptors blockers on mortality in acute heart failure patients with left ventricular systolic dysfunction in the middle east

T2 - Observations from the Gulf Acute Heart Failure Registry (Gulf CARE)

AU - Al-Zakwani, Ibrahim

AU - Sulaiman, Kadhim

AU - Al-Lawati, Jawad A.

AU - Alsheikh-Ali, Alawi A.

AU - Panduranga, Prashanth

AU - Al-Habib, Khalid F.

AU - Al Suwaidi, Jassim

AU - Al-Mahmeed, Wael

AU - Al-Faleh, Hussam

AU - Elasfar, Abdelfatah

AU - Al-Motarreb, Ahmed

AU - Ridha, Mustafa

AU - Bulbanat, Bassam

AU - Al-Jarallah, Mohammed

AU - Bazargani, Nooshin

AU - Asaad, Nidal

AU - Amin, Haitham

PY - 2018/1/1

Y1 - 2018/1/1

N2 - Aims: To evaluate the impact of Angiotensin-Converting Enzyme Inhibitors (ACEIs)/ Angiotensin Receptors Blockers (ARBs) on in-hospital, 3-and 12-month all-cause mortality in Acute Heart Failure (AHF) patients with left ventricular systolic dysfunction in 7 countries of the Middle East. Methods and Results: Data was analysed from 2,683 consecutive patients admitted with AHF and Left Ventricular Ejection Fraction (LVEF) (<40%) from 47 hospitals from February to November 2012. Analyses were evaluated using univariate and multivariate statistics. The overall mean age of the cohort was 58±15, 72% (n=1,937) were males, 62% (n=1,651) had coronary artery disease, 57% (n=1,539) were hypertensives and 47% (n=1,268) had diabetes. Overall cumulative mortality at inhospital, 3-and 12-month follow-up was 5.8% (n=155), 12.6% (n=338) and 20.4% (n=548), respectively. Adjusting for demographic and clinical characteristics as well as medication in a multivariate logistic regression model, ACEIs were associated with lower risk of in-hospital mortality (adjusted odds ratio (aOR), 0.48; 95% Confidence Interval (CI): 0.25 to 0.94; p=0.031). At 3-month follow-up, both ACEIs (aOR, 0.64; 95% CI: 0.43 to 0.95; p=0.025) and ARBs (aOR, 0.34; 95% CI: 0.18 to 0.62; p<0.001) were associated with lower risk of mortality. Additionally, at 12-month follow-up, those prescribed ACEIs (aOR, 0.71; 95% CI: 0.53 to 0.96; p=0.027) and ARBs (aOR, 0.47; 95% CI: 0.31 to 0.71; p<0.001) were still associated with lower risk of mortality. Conclusion: ACEIs and ARBs treatments were associated with lower mortality risk during admission and up to 12-month of follow-up in Middle East AHF patients with left ventricular systolic dysfunction.

AB - Aims: To evaluate the impact of Angiotensin-Converting Enzyme Inhibitors (ACEIs)/ Angiotensin Receptors Blockers (ARBs) on in-hospital, 3-and 12-month all-cause mortality in Acute Heart Failure (AHF) patients with left ventricular systolic dysfunction in 7 countries of the Middle East. Methods and Results: Data was analysed from 2,683 consecutive patients admitted with AHF and Left Ventricular Ejection Fraction (LVEF) (<40%) from 47 hospitals from February to November 2012. Analyses were evaluated using univariate and multivariate statistics. The overall mean age of the cohort was 58±15, 72% (n=1,937) were males, 62% (n=1,651) had coronary artery disease, 57% (n=1,539) were hypertensives and 47% (n=1,268) had diabetes. Overall cumulative mortality at inhospital, 3-and 12-month follow-up was 5.8% (n=155), 12.6% (n=338) and 20.4% (n=548), respectively. Adjusting for demographic and clinical characteristics as well as medication in a multivariate logistic regression model, ACEIs were associated with lower risk of in-hospital mortality (adjusted odds ratio (aOR), 0.48; 95% Confidence Interval (CI): 0.25 to 0.94; p=0.031). At 3-month follow-up, both ACEIs (aOR, 0.64; 95% CI: 0.43 to 0.95; p=0.025) and ARBs (aOR, 0.34; 95% CI: 0.18 to 0.62; p<0.001) were associated with lower risk of mortality. Additionally, at 12-month follow-up, those prescribed ACEIs (aOR, 0.71; 95% CI: 0.53 to 0.96; p=0.027) and ARBs (aOR, 0.47; 95% CI: 0.31 to 0.71; p<0.001) were still associated with lower risk of mortality. Conclusion: ACEIs and ARBs treatments were associated with lower mortality risk during admission and up to 12-month of follow-up in Middle East AHF patients with left ventricular systolic dysfunction.

KW - Angiotensin receptor antagonists

KW - Angiotensin-converting enzyme inhibitors

KW - Ejection fraction

KW - Heart failure

KW - Middle East

KW - Mortality

UR - http://www.scopus.com/inward/record.url?scp=85053802478&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85053802478&partnerID=8YFLogxK

U2 - 10.2174/1570161115666170817164420

DO - 10.2174/1570161115666170817164420

M3 - Article

VL - 16

SP - 596

EP - 602

JO - Current Vascular Pharmacology

JF - Current Vascular Pharmacology

SN - 1570-1611

IS - 6

ER -